Plasma prostaglandins in mucositis due to radiotherapy and chemotherapy for head and neck cancer

Tanner, N.S.B.; Stamford, I F; Bennett, A. B.

doi:10.1038/bjc.1981.114

Cited by 35 publications

(15 citation statements)

References 13 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The slower fall in 6-oxo-PGF1I in these patients after radiotherapy may indicate a slower rate of tumour regression. However, the inflammatory response of irradiated tissues may stimulate PGJ2 production (Tanner et al, 1981) which masks the fall in production by tumour tissue. Therefore in these patients plasma 6-oxo-PGF,oa may not be initially such an accurate marker for the clinical response of the tumour itself, though it undoubtedly is at follow-up.…”

Section: Discussionmentioning

confidence: 99%

Peripheral plasma immunoreactive 6-oxo-postaglandin F1 α and gynaecological tumours

Alam¹,

Jogee²,

MacGregor³

et al. 1982

Br J Cancer

View full text Add to dashboard Cite

Summary.-Peripheral plasma levels of immunoreactive 6-oxo-PGF1a, the stable hydrolysis product of prostacyclin, were significantly higher in female patients with tumours of the genital tract than in normal controls. In the groups with malignant tumours, these high levels declined after operation and/or radiotherapy if the tumour responded to treatment. In patients who did not respond to treatment or with tumour recurrence, levels of plasma 6-oxo-PGF,a remained high or even rose further. Benign gynaecological tumours were also associated with significantly raised plasma 6-oxo-PGFjoc levels, and these fell to normal levels immediately on surgical removal of the tumour. Possible reasons for these alterations are described. Further investigations are warranted to see whether serial measurements of plasma 6-oxo-PGF,a. could be used as a prognostic index for the clinical status of patients with gynaecological tumours.

show abstract

Section: Discussionmentioning

confidence: 99%

Peripheral plasma immunoreactive 6-oxo-postaglandin F1 α and gynaecological tumours

Alam¹,

Jogee²,

MacGregor³

et al. 1982

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…The main property of cancer cells is rapid division. Chemotherapy acts by killing cells that divide rapidly, which means it also harms cells that divide rapidly under normal circumstances such as cells in the bone marrow, digestive tract, and hair follicles, producing side effects such as myelosuppression, 2 mucosities, 3 and alopecia. 4 To overcome these side effects, researchers are now searching for efficient and safe transport carriers, which prolong exposure time to drugs and target cancerous cells without targeting healthy cells.…”

Section: Introductionmentioning

confidence: 99%

Development of antiproliferative nanohybrid compound with controlled release property using ellagic acid as the active agent

Ali¹,

Zainal²,

Hakim³

et al. 2011

IJN

View full text Add to dashboard Cite

An ellagic acid (EA)–zinc layered hydroxide (ZLH) nanohybrid (EAN) was synthesized under a nonaqueous environment using EA and zinc oxide (ZnO) as the precursors. Powder X-ray diffraction showed that the basal spacing of the nanohybrid was 10.4 Å, resulting in the spatial orientation of EA molecules between the interlayers of 22.5° from z-axis with two negative charges at 8,8′ position of the molecules pointed toward the ZLH interlayers. FTIR study showed that the intercalated EA spectral feature is generally similar to that of EA, but with bands slightly shifted. This indicates that some chemical bonding of EA presence between the nanohybrid interlayers was slightly changed, due to the formation of host–guest interaction. The nanohybrid is of mesopores type with 58.8% drug loading and enhanced thermal stability. The release of the drug active, EA from the nanohybrid was found to be sustained and therefore has good potential to be used as a drug controlled-release formulation. In vitro bioassay study showed that the EAN has a mild effect on the hepatocytes cells, similar to its counterpart, free EA.

show abstract

“…FLU or INDO might improve the response of cancer patients to chemotherapy or radiotherapy. Cancer patients may take PGS inhibitors for various ailments, and aspirin may even be prescribed to relieve effects of cancer treatment, such as diarrhoea after pelvic irradiation (Mennie et al, 1975) or mucositis (O'Connor et al, 1977;Tanner, et al, 1981). Other drugs which can inhibit PGS include the anti-oestrogen tamoxifen (Ritchie, 1978) and the corticosteroid prednisone (Gryglewski et al, 1975).…”

Section: Discussionmentioning

confidence: 99%

Increased survival of cancer-bearing mice treated with inhibitors of prostaglandin synthesis alone or with chemotherapy

Bennett¹,

Berstock²,

Carroll³

1982

Br J Cancer

Self Cite

View full text Add to dashboard Cite

Summary.-In mice with a transplantable mammary carcinoma, treatment with the prostaglandin-synthesis inhibitors flurbiprofen or indomethacin produced various beneficial effects. Survival time after excision of the transplanted tumour was increased, particularly when the drugs were given with the chemotherapeutic agents methrotrexate and melphalan, and there were more disease-free survivors. The combined treatment with flurbiprofen also gave less tumour recurrence at the excision site. Flurbiprofen did not seem to alter the bioavailability of the chemotherapeutic agents.

show abstract

Plasma prostaglandins in mucositis due to radiotherapy and chemotherapy for head and neck cancer

Cited by 35 publications

References 13 publications

Peripheral plasma immunoreactive 6-oxo-postaglandin F1 α and gynaecological tumours

Peripheral plasma immunoreactive 6-oxo-postaglandin F1 α and gynaecological tumours

Development of antiproliferative nanohybrid compound with controlled release property using ellagic acid as the active agent

Increased survival of cancer-bearing mice treated with inhibitors of prostaglandin synthesis alone or with chemotherapy

Contact Info

Product

Resources

About